Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Altamira Therapeutics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CYTO
Nasdaq
8731
https://aurismedical.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Altamira Therapeutics Ltd
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
- Mar 25th, 2024 12:47 pm
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
- Feb 7th, 2024 1:47 pm
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
- Jan 24th, 2024 1:47 pm
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
- Jan 8th, 2024 1:47 pm
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Dec 29th, 2023 1:47 pm
Altamira Therapeutics Provides Investor and Business Update
- Dec 11th, 2023 1:00 pm
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
- Dec 5th, 2023 5:54 pm
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
- Nov 29th, 2023 3:20 pm
Trending tickers: Microsoft | Bitcoin | Altamira | Ashtead
- Nov 20th, 2023 11:08 am
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
- Nov 17th, 2023 2:04 pm
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
- Nov 10th, 2023 1:47 pm
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
- Sep 14th, 2023 12:47 pm
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
- Sep 12th, 2023 11:30 am
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
- Sep 6th, 2023 12:47 pm
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
- Aug 23rd, 2023 12:47 pm
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
- Jul 20th, 2023 12:47 pm
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
- Jul 17th, 2023 12:47 pm
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
- Jul 6th, 2023 12:00 pm
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
- Jul 5th, 2023 12:47 pm
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
- Jun 15th, 2023 12:47 pm
Scroll